Patents Assigned to Xencor
  • PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
    Patent number: 11524991
    Abstract: The present invention is directed to novel PD-1-targeted IL-15/R?-Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/R?-Fc fusion proteins can be administered to a patient to treat cancer.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 13, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
    Publication number: 20220389098
    Abstract: The present disclosure relates to immunoglobulins that bind Fc?RIIb+ B cells and coengage CD19 on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
    Type: Application
    Filed: May 16, 2022
    Publication date: December 8, 2022
    Applicant: Xencor, Inc.
    Inventors: Debra Zack, John H. Stone, Shiv Pillai, Paul Foster
  • IL-7-FC-fusion proteins
    Patent number: 11512122
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 29, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
    Patent number: 11505595
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: November 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • Bispecific checkpoint inhibitor antibodies
    Patent number: 11492407
    Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: November 8, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh S. Muchhal
  • Heterodimeric antibodies that bind ENPP3 and CD3
    Patent number: 11472890
    Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Rumana Rashid, Umesh S. Muchhal, Gregory Moore, Alex Nisthal, Seung Chu, Sung-Hyung Lee, Yoon Kyung Kim
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11447552
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 20, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11434295
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 6, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Heterodimeric Fc variants
    Patent number: 11401348
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 2, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Gregory Moore
  • PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
    Patent number: 11377477
    Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 5, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Rajat Varma
  • Methods of treating neurological diseases
    Patent number: 11365229
    Abstract: The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-?.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: June 21, 2022
    Assignee: XENCOR, INC.
    Inventors: David Szymkowski, Malu Tansey, Lesley Probert
  • Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
    Patent number: 11365256
    Abstract: The present disclosure relates to immunoglobulins that bind Fc?RIIb+ B cells and coengage CD19 on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 21, 2022
    Assignee: XENCOR, INC.
    Inventors: Debra Zack, John H. Stone, Shiv Pillai, Paul Foster
  • IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11358999
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: June 14, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 11352442
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • CTLA4-IG immunoadhesins
    Patent number: 11352412
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Engineered IL-2 Fc fusion proteins
    Patent number: 11319355
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 3, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • Bispecific and monospecific antibodies using novel anti-PD-1 sequences
    Patent number: 11312770
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 26, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • Heterodimeric proteins
    Patent number: 11299554
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 12, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • CTLA4-Ig immunoadhesins
    Patent number: 11254727
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Bispecific checkpoint inhibitor antibodies
    Patent number: 11236170
    Abstract: The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: February 1, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal